Literature DB >> 6295428

Modification by WR 2721 of the response to chemotherapy of tumours and normal tissues in the mouse.

P R Twentyman.   

Abstract

The sulphydryl compound WR 2721 has been combined with a range of cytotoxic drugs in the mouse and the effects upon tumours and normal tissues determined. In the acute lethality (LD50/30) assay, mean protection factors produced by WR 2721 (200 or 400 mg kg-1) were generally less than 1.3 for cyclophosphamide (CTX), CCNU and chlorambucil (CHL) but a protection factor of 1.7 was obtained for cisplatinum (cis-P) in combination with 400 mg kg-1 of WR 2721. No protection against the depression of peripheral white cell count seen at 3 days after CTX, CCNU or cis-P was obtained with either 200 or 400 mg kg-1 of WR 2721. Significant protection of the RIF-1 sarcoma by WR 2721 against CTX and cis-P induced growth delay was seen. In the KHT sarcoma, WR 2721 produced small reductions in the growth delay caused by CCNU, melphalan and CHL but these were not statistically significant. These data show less differential normal tissue protection by WR 2721 than do a number of reports in the literature.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6295428      PMCID: PMC2011245          DOI: 10.1038/bjc.1983.7

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin.

Authors:  P R Twentyman; R F Kallman; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

2.  Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.

Authors:  T H Wasserman; T L Phillips; G Ross; L J Kane
Journal:  Cancer Clin Trials       Date:  1981

3.  Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.

Authors:  J M Yuhas; F Culo
Journal:  Cancer Treat Rep       Date:  1980-01

4.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.

Authors:  R F Kallman; G Silini; L M Van Putten
Journal:  J Natl Cancer Inst       Date:  1967-09       Impact factor: 13.506

5.  Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.

Authors:  J M Yuhas
Journal:  Cancer Treat Rep       Date:  1979-06

6.  A new mouse tumor model system (RIF-1) for comparison of end-point studies.

Authors:  P R Twentyman; J M Brown; J W Gray; A J Franko; M A Scoles; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

7.  Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.

Authors:  J M Yuhas
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

8.  Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice.

Authors:  L Milas; N Hunter; B O Reid; H D Thames
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

9.  Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

10.  Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.

Authors:  J M Yuhas; J M Spellman; S W Jordan; M C Pardini; S M Afzal; F Culo
Journal:  Br J Cancer       Date:  1980-10       Impact factor: 7.640

View more
  3 in total

1.  Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.

Authors:  F M Boyle; H R Wheeler; G M Shenfield
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 2.  Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

3.  Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.

Authors:  A E Korst; E Boven; M L van der Sterre; A M Fichtinger-Schepman; W J van der Vijgh
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.